FPR1 |
P21462
|
formyl peptide receptor 1
|
G-protein coupled receptor
|
|
0.576 |
0.769 |
HLA-DRB4 |
P13762
|
major histocompatibility complex, class II, DR beta 4
|
Immune response
|
|
0.565 |
0.846 |
IFNA1 |
P01562
|
interferon alpha 1
|
|
|
0.371 |
0.923 |
IFNA13 |
P01562
|
interferon alpha 13
|
|
|
0.374 |
0.923 |
IFNB1 |
P01574
|
interferon beta 1
|
|
|
0.421 |
0.846 |
KIR2DS4 |
P43632
|
killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 4
|
Receptor
|
|
0.674 |
0.500 |
MAA |
|
microphthalmia or anophthalmia and associated anomalies
|
|
|
0.666 |
0.577 |
MMP12 |
P39900
|
matrix metallopeptidase 12
|
Enzyme
|
|
0.484 |
0.885 |
COX2 |
P00403
|
cytochrome c oxidase subunit II
|
Enzyme
|
|
0.352 |
0.962 |
NM |
|
neutrophil migration
|
|
|
0.473 |
0.808 |
PECAM1 |
P16284
|
platelet and endothelial cell adhesion molecule 1
|
Cell adhesion
|
|
0.426 |
0.846 |
RNASE3 |
P12724
|
ribonuclease A family member 3
|
|
|
0.490 |
0.808 |
SRY |
Q05066
|
sex determining region Y
|
Transcription factor
|
|
0.456 |
0.808 |
TRBV20OR9-2 |
|
T cell receptor beta variable 20/OR9-2 (non-functional)
|
|
|
0.403 |
0.923 |
TDGF1P3 |
P51864
|
teratocarcinoma-derived growth factor 1 pseudogene 3
|
Calcium-binding protein
|
|
0.631 |
0.500 |
CDR3 |
|
Cerebellar degeneration-related autoantigen-3
|
|
|
0.472 |
0.808 |
TAM |
|
Myeloproliferative syndrome, transient (transient abnormal
|
|
|
0.528 |
0.731 |
LOH19CR1 |
|
loss of heterozygosity, 19, chromosomal region 1
|
|
|
0.569 |
0.808 |
HCP5 |
Q6MZN7
|
HLA complex P5
|
|
|
0.595 |
0.808 |
FAM215A |
Q9Y5M1
|
family with sequence similarity 215 member A
|
|
|
0.650 |
0.500 |
PART1 |
|
prostate androgen-regulated transcript 1
|
|
|
0.483 |
0.885 |
TRBV20-1 |
A0A075B6N2
|
T cell receptor beta variable 20-1
|
|
|
0.821 |
0.346 |
UHRF1 |
Q96T88
|
ubiquitin like with PHD and ring finger domains 1
|
|
|
0.540 |
0.692 |
MEG3 |
|
maternally expressed 3
|
|
|
0.471 |
0.846 |
RBPJP4 |
|
RBPJ pseudogene 4
|
|
|
0.805 |
0.423 |